Physician profile
Dwight Clarke
NPI 1477555845
$18,428.99
in general payments reported to CMS, 2019-2025
27 companies · $2,049 in 2025
The $2,049 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,770 · 2020: $2,319 · 2021: $2,404 · 2022: $2,951 · 2023: $2,934 · 2024: $3,003 · 2025: $2,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,699 · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,699.25 |
| Education | $285.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,383.53 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $2,748.37 | 2019-2025 | Yeztugo, Veklury |
| Merck Sharp & Dohme LLC | $1,824.63 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Insmed, INC. | $1,217.14 | 2019-2025 | Arikayce |
| Abbvie INC. | $1,137.56 | 2021-2025 | Teflaro, Avycaz, Dalvance |
| Janssen Biotech, INC. | $935.39 | 2019-2023 | Symtuza |
| Astellas Pharma US INC | $878.69 | 2019-2025 | Cresemba |
| Melinta Therapeutics, LLC | $867.38 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Paratek Pharmaceuticals, INC. | $781.99 | 2020-2025 | Nuzyra |
| Allergan, INC. | $577.56 | 2019-2020 | |
| Shionogi INC | $512.13 | 2022-2025 | Fetroja |
| Theratechnologies INC. | $446.39 | 2019-2025 | Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $415.30 | 2019-2025 | Mytesi |
| Mayne Pharma Commercial LLC | $331.38 | 2020-2022 | |
| Emd Serono, INC. | $315.39 | 2019-2025 | Serostim |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $295.64 | 2022-2024 | Livtencity |
| La Jolla Pharmaceutical Company | $198.59 | 2021-2025 | Xerava, Xacduro, Zevtera |
| Janssen Products, LP | $169.99 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $119.09 | 2019-2023 | Symtuza |
| Tetraphase Pharmaceuticals, INC. | $97.11 | 2019-2020 | |
| Vyera Pharmaceuticals, LLC | $49.53 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $33.83 | 2022 | |
| Eurofins Viracor, LLC | $21.89 | 2019 | |
| Dynavax Technologies Corporation | $21.77 | 2021 | |
| Ethicon US, LLC | $20.39 | 2022 | |
| Nabriva Therapeutics, Plc | $14.78 | 2021 | |
| Agios Pharmaceuticals, INC. | $13.55 | 2023 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.